Long-Term Cardiovascular Benefits Associated With Sodium-Glucose Cotransporter 2 Inhibitors
SGLT2 inhibitors were associated with a decreased risk for acute kidney injury, but researchers observed an increased risk for urinary tract infections.
Approximately 1% of individuals in the United States have a genetic predisposition to cancer or heart disease, and these individuals could be ideal candidates for genetic screening.
Among US dialysis patients, cardiovascular event rates are highest in those with diabetic nephropathy and lowest among those with IgA nephropathy.
However, the temporary increase in type 2 diabetes risk does not attenuate benefits on total and CVD mortality.